Treatment of Adolescent Suicide Attempters (TASA) - Full Text View

Purpose

The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.

Condition	Intervention	Phase
Depression Suicide, Attempted	Drug: fluoxetine Drug: sertraline Drug: citalopram Drug: escitalopram Drug: bupropion Drug: mirtazapine Drug: venlafaxine Drug: lithium Behavioral: Cognitive Behavioral Therapy	Phase II Phase III

MedlinePlus related topics:

Depression Suicide

Drug Information available for:

Sertraline hydrochloride Sertraline Fluoxetine Escitalopram Benzetimide Citalopram Citalopram hydrobromide Dexetimide Escitalopram oxalate Bupropion hydrochloride Bupropion Mirtazapine Venlafaxine Venlafaxine hydrochloride Fluoxetine hydrochloride Lithium carbonate Lithium citrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by National Institute of Mental Health (NIMH):

Estimated Enrollment:	120
Study Start Date:	March 2004
Study Completion Date:	June 2007

Detailed Description:

Suicide is the third leading cause of death in adolescents and is a major public health problem. Depression is the most common diagnosis for adolescent suicide attempts. Little is known about what treatment is best for these adolescents since they are usually excluded from participation in research studies.

Participants in this study will be randomly assigned to receive carefully monitored antidepressant medication with routine support and management, cognitive behavioral therapy (CBT), or a combination of antidepressant medication plus CBT.

Eligibility

Ages Eligible for Study:	12 Years to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

At least one suicide attempt or interrupted attempt within the past 45 days
Continuously reside with a primary caretaker (parent, legal guardian, foster parent) for at least 6 months that can provide legal consent

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00080158

Locations


United States, Maryland
	Johns Hopkins University
	Baltimore, Maryland, United States, 21287

United States, New York
	Columbia University at the New York State Psychiatric Institute
	New York, New York, United States, 10032
	New York University Child Study Center
	New York, New York, United States, 10016

United States, North Carolina
	Duke University Medical Center
	Durham, North Carolina, United States, 27705

United States, Pennsylvania
	University of Pittsburgh - Western Psychiatric Institute and Clinic
	Pittsburgh, Pennsylvania, United States, 15213

United States, Texas
	University of Texas, Southwestern Medical Center
	Dallas, Texas, United States, 75235

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

Investigators


Study Chair:	Laurence Greenhill, MD

More Information

Study ID Numbers:	U10 MH66762, U10 MH066775, U10 MH066778, U10 MH066769, U10 MH066750, DDTR B4-ARD
First Received:	March 24, 2004
Last Updated:	July 17, 2008
ClinicalTrials.gov Identifier:	NCT00080158
Health Authority:	United States: Food and Drug Administration

Keywords provided by National Institute of Mental Health (NIMH):

Dysthymic Disorder

Adolescent

Study placed in the following topic categories:

Depression

Suicide, Attempted

Suicide

Lithium Carbonate

Mirtazapine

Depressive Disorder

Citalopram

Serotonin

Histamine

Behavioral Symptoms

Fluoxetine

Venlafaxine

Bupropion

Histamine phosphate

Sertraline

Dysthymic Disorder

Dexetimide

Lithium

Self-Injurious Behavior

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors

Neurotransmitter Agents

Adrenergic Agents

Molecular Mechanisms of Pharmacological Action

Physiological Effects of Drugs

Psychotropic Drugs

Histamine Agents

Adrenergic alpha-Antagonists

Serotonin Uptake Inhibitors

Pharmacologic Actions

Antidepressive Agents, Tricyclic

Serotonin Agents

Histamine Antagonists

Therapeutic Uses

Histamine H1 Antagonists

Adrenergic Antagonists

Antidepressive Agents, Second-Generation

Central Nervous System Agents

Antidepressive Agents

ClinicalTrials.gov processed this record on November 03, 2008

Sponsored by:	National Institute of Mental Health (NIMH)
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00080158